The Samsung Biologics tender offer for PolyPeptide Group AG (announced July 20 at CHF 44.31 per share, CHF 1.46 billion / $1.8 billion, 40% premium) continued through Sunday September 6, 2026 in the 10 SIX Swiss Exchange trading-day cooling-off period that began September 1 following Samsung Peptide AG's August 31 publication of the formal tender offer prospectus. Under Swiss takeover law, the main offer period commences Tuesday September 15, 2026 and runs through October 12, 2026 at 4 p.m. Swiss time. Closing conditions include a 66⅔% minimum acceptance threshold plus customary regulatory approvals. Draupnir Holding B.V. (approximately 55.65% of PolyPeptide shares outstanding) has committed to tender all of its shares. Transaction close is targeted for end of 2026, after which Samsung intends to squeeze out remaining minorities and delist PolyPeptide, integrating the Malmö, Limhamn, Strasbourg, Braine-l'Alleud, and Torrance sites into Samsung's Incheon multi-modality footprint. The transaction will consolidate one of the top three global peptide CDMO capacity positions alongside Bachem and CordenPharma.
The Samsung Biologics tender offer for PolyPeptide Group AG (announced July 20 at CHF 44.31 per share, CHF 1.46 billion / $1.8 billion) entered its 10 SIX Swiss Exchange trading-day cooling-off period Tuesday September 1, 2026 following the Monday August 31 publication of the formal tender offer prospectus by Samsung's Swiss subsidiary Samsung Peptide AG. The main offer period commences Tuesday September 15 and runs through October 12, 2026 at 4 p.m. Swiss time. Closing conditions include a 66⅔% minimum acceptance threshold plus customary regulatory approvals. Draupnir Holding B.V. (approximately 55.65% of PolyPeptide shares outstanding) has already committed to tender all of its shares. Transaction close is targeted for end of 2026, after which Samsung intends to squeeze out remaining minorities and delist PolyPeptide from SIX, integrating the Malmö, Limhamn, Strasbourg, Braine-l'Alleud, and Torrance sites into Samsung's Incheon multi-modality footprint alongside the existing monoclonal antibody and antibody-drug conjugate operations.
Samsung Biologics (KRX: 207940), through its Swiss subsidiary Samsung Peptide AG, published Monday August 31, 2026 the formal tender offer prospectus for all publicly held registered shares of PolyPeptide Group AG (SIX: PPGN) on SIX Swiss Exchange. Terms: CHF 44.31 net in cash per share (implied equity value approximately CHF 1.46 billion / $1.8 billion, a 40% premium to the CHF 31.65 undisturbed share price of April 10, 2026). The cooling-off period runs 10 SIX trading days from September 1, and the main offer period commences September 15, 2026 through October 12, 2026 at 4 p.m. Swiss time. Draupnir Holding B.V. (approximately 55.65% of PolyPeptide shares) has committed to tender all shares. Closing conditions include a 66⅔% minimum acceptance threshold plus customary regulatory approvals; transaction close is targeted for end of 2026. Samsung intends to squeeze out remaining minorities and delist PolyPeptide post-close, integrating the Malmö, Limhamn, Strasbourg, Braine-l'Alleud, and Torrance sites into the Incheon multi-modality biologics footprint.